Fangda has renowned expertise in China’s complex antitrust and competition laws and regulations. We provide clients with insight into the regulatory environment and clear guidance on strategy to help them secure their commercial objectives quickly and efficiently.
Our team has a market-leading track record of successfully assisting clients on some of the most high-profile merger filings and antitrust investigations in China. Clients benefit from our longstanding engagement with China’s competition regulators, so they always know where the regulators stand.
We currently have a dedicated competition team in China comprising of 20 competition law specialists who work across all our offices. Members of our team have practiced in many jurisdictions, including Hong Kong, the EU, the UK, the U.S., and Australia. We deliver local expertise with an international perspective.
We have expertise in the following areas:
Merger control
We work to ensure optimal outcomes for clients when they apply for merger clearance. This includes advising on the likelihood of intervention by China’s competition authority and ensuring that the strategy for obtaining clearance in China is aligned with filings in other jurisdictions. Where remedies are required, we design and negotiate innovative solutions to address any competition concerns without losing sight of the commercial objectives of the deal in China and globally.
Antitrust investigation and litigation
We support our clients in assessing any risks of investigation and collaborate to determine the best strategy. This includes responding to dawn raids, framing leniency applications and managing large-scale document reviews and requests. By effectively navigating regulatory processes and communications, we have successfully defended clients in many landmark cases. We have helped shape the way that antitrust law is applied in many industries.
Where litigation is unavoidable, we have a reputation for successfully fighting our clients’ corner. Our competition and antitrust lawyers work closely with our dispute resolution lawyers to deliver a seamless service and some of our team have experience in both fields.
Compliance and advisory
We provide clients with strategic advice on pricing, distribution, licensing and supply agreements, and also carry out full-scale competition law compliance audits. Clients look to us to help them ensure compliance without undermining their business objectives.
我们的全方位业务领域:
Recognition
-
- Competition/Antitrust (PRC Firms) - Band 1
-
Chambers Greater China, 2022-2025
-
- Competition/Antitrust (PRC Firms) - Band 1
-
Chambers Asia-Pacific, 2018-2021
-
- Antitrust and Competition: PRC firms - Tier 1
-
The Legal 500 Asia Pacific, 2017-2025
-
- Competition Firm of the Year - China
-
China Law and Practice, 2017-2020
-
- Competition/Antitrust - Outstanding
-
Asialaw Profiles, 2018-2025
-
- GCR100 Chinese Law Firm - Elite
-
Global Competition Review (GCR) 100, China Jurisdiction, 2018-2025
-
- Merger Control Matter of The Year – Asia-Pacific, Middle East and Africa: ZF Friedrichshafen/WABCO
-
Global Competition Review (GCR) Awards, 2021
Notable Matters
- Novelis on its US$2.6 billion acquisition of Aleris Corporation, which was conditionally approved by the Chinese competition authority.
- Cargotec on its €87 million acquisition of the marine and offshore business from TTS Group, which was conditionally approved by the Chinese competition authority.
- Boeing on its US$4.75 billion acquisition of the commercial jet business division of Embraer.
- Rockwell Collins on its US$30 billion acquisition of United Technologies Corporation, which was conditionally approved by the Chinese competition authority.
- Linde Group on its €66 billion merger with Praxair, which was conditionally approved by the Chinese competition authority.
- The Walt Disney Company and 21st Century Fox, Inc. on Disney’s US$71.3 billion acquisition of Fox.
- DuPont on its US$130 billion merger with the Dow Chemical Company, which was conditionally approved by the Chinese competition authority.
- Becton, Dickinson and Company on its US$24 billion merger with C.R. Bard, which was conditionally approved by the Chinese competition authority.
- Broadcom on its proposed US$117 billion acquisition of Qualcomm.
- AB InBev on the Chinese merger control aspects of its acquisition of SAB Miller for US$104 billion, which was conditionally approved by the Chinese competition authority.
- Jude Medical on its US$25 billion merger with Abbott Laboratories, which was conditionally approved by the Chinese competition authority..
- Baosteel on its merger with Wuhan Steel, creating one of the largest steel manufacturers in the world.
- Konecranes on its US$6.1 billion acquisition of Terex Corporation.
- Nokia on its €15.6 billion acquisition of Alcatel-Lucent, which was conditionally approved by the Chinese competition authority.
- Canon on its US$6 billion acquisition of Toshiba Medical.
- Schlumberger and Cameron on Schlumberger’s US$14.8 billion acquisition of Cameron.
- Albemarle on its US$2 billion acquisition of Rockwood.
- Merck on its US$17 billion acquisition of Sigma-Aldrich.
- EMC on its US$67 billion merger with Dell.
- A multinational shipping company accused of cartel conduct, resulting in the first acquittal of a multinational company.
- An international shipping company in a cartel investigation initiated by the National Development and Reform Commission (NDRC), which resulted in the investigation being suspended.
- Three state-owned port groups in an NDRC antitrust investigation into alleged abuse of dominance. The NDRC dropped its charges against one of the groups and suspended its investigation of the remaining two.
- A leading international company in the entertainment industry in an abuse of dominance investigation.
- An international chemical company in the first abuse of dominance investigation initiated by a local antitrust authority in this sector.
- An international medical device company in the first and largest antitrust investigation in the medical device sector.
- Three multinational automobile companies in their respective dawn raids and antitrust investigation into resale price maintenance practice.
- A multinational chemical company in an investigation into resale price maintenance practice.
- A European consumer goods manufacturer in an investigation into resale price maintenance initiated by the local Development and Reform Commission.
- A U.S. company in settling an NDRC antitrust investigation into alleged abuse of dominance involving standard essential patents. The NDRC did not impose any fines or penalties.
- A multinational technology company in handling a State Administration for Market Regulation (SAMR) investigation involving alleged abuse of dominance through license schemes.
- A multinational high-tech company in a series of antitrust civil cases concerning the license of its patent portfolio connected with telecommunication standards.
- A multinational software company in its defense against antitrust claims filed by distributors on the grounds of abuse of market dominance.
- A global communications technology company in a dispute over alleged abuse of market dominance relating to restrictive provisions in intellectual property license agreements.
- An electrical equipment manufacturing company in a dispute with a global energy company over alleged abuse of market dominance concerning restrictive provisions in supply agreements.
- A multinational chemicals company raising an antitrust claim for abuse of market dominance against a U.S.-based petrochemical company concerning restrictive provisions in supply agreements.
- A Japanese company in defending allegations following a decision by the EU Commission involving an alleged international cartel.
- A leading Chinese internet company on antitrust and competition compliance issues concerning alleged abuse of dominance and technology licensing.
- A multinational manufacturer in analyzing sensitive information exchange issues between its affiliates and joint venture partners.
- A world-leading sporting goods company on competition concerns in connection with distribution and franchising agreements in China and Hong Kong.
- A multinational cement company in antitrust compliance, in particular risks of cartel and sensitive information exchange.
- A number of Japanese conglomerates/companies on antitrust compliance in China involving vertical restraints and abuse of dominance.
- A number of multinational pharmaceutical companies on competition concerns relating to distribution and commercialization arrangements in the context of medical reform.
- A number of multinational companies in formulating or revising their antitrust compliance manuals and policies.
Further Reading
News
Publications
Articles
-
-
2025 / 10 / 28
Fangda's China and Singapore offices advise Midea Group on cross-border acquisition and European joint venture
-
-
-
2025 / 08 / 12
A-Share Market’s First Cross-Border Share Swap Transaction - Fangda assists ASMPT in selling AAMI’s equity to Zhizheng
-
-
-
2025 / 03 / 01
2024 Antitrust China Annual Review
-
-
-
2024 / 03 / 14
Antitrust China Annual Review 2023
-
-
-
2023 / 11 / 01
Antitrust China Annual Review 2022
-
-
-
2022 / 08 / 31
Antitrust China 2021 Annual Review
-
-
-
2021 / 12 / 26
Antitrust China 2020 Annual Review
-
-
-
2025 / 08 / 06
Below Notification Thresholds ≠ No Risk: Antitrust Merger Review Trends Seen from Recent Below-Threshold Cases
-
-
-
2025 / 02 / 12
Fangda contributed to Chambers Investing In China 2025
-
-
-
2025 / 01 / 15
Unequal playing field: China’s Ministry of Commerce concludes that EU Foreign Subsidy Regulation prevents Chinese entry and competitiveness
-
-
-
2024 / 11 / 13
Key Takeaways of China's New Antitrust Guidelines for Standard Essential Patents
-
-
-
2024 / 08 / 22
Fangda Opinion: New Regulations on Fair Competition Review effective since 1 August: How would it affect Government’s Financial and Tax Incentives?
-
-
-
2024 / 08 / 19
China Introduces New Rules on Merger Control: the Draft Guidelines for Discretionary Standards in Determining Penalties for Illegal Implementation of Concentration
-
-
-
2024 / 07 / 31
HALF YEAR SNAPSHOT: Merger control developments in China in 2024 so far
-
-
-
2024 / 07 / 04
Ten key trends and impact on antitrust civil litigation as China’s Supreme People's Court finalized new judicial interpretation
-
-
-
2024 / 07 / 01
China releases consultation draft for horizontal merger review guidelines: What do dealmakers need to know?
-
-
-
2024 / 04 / 29
Lexology In-Depth: Cartels and Leniency - Edition 12
-
-
-
2024 / 02 / 20
Chambers and Partners: Investing In China 2024
-
-
-
2024 / 01 / 29
New Filing Thresholds for China Merger Control: What Dealmakers Need to Know
-


